HM Payson & Co’s GSK GSK Stock Holding History

HM Payson & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$229K	Sell	4,374 -480	-10%	-$25.4K	﹤0.01%	427
2026 Q1	$268K	Buy	4,854 +480	+11%	+$26K	﹤0.01%	387
2025 Q4	$215K	Hold	4,374	–	–	﹤0.01%	411
2025 Q3	$189K	Buy	4,374 +384	+10%	+$15K	﹤0.01%	442
2025 Q2	$153K	Buy	3,990 +2,682	+205%	+$102K	﹤0.01%	464
2025 Q1	$50.7K	Buy	1,308 +580	+80%	+$21.2K	﹤0.01%	640
2024 Q4	$24.6K	Hold	728	–	–	﹤0.01%	752
2024 Q3	$29.8K	Hold	728	–	–	﹤0.01%	711
2024 Q2	$28K	Sell	728 -181	-20%	-$7.61K	﹤0.01%	698
2024 Q1	$39K	Hold	909	–	–	﹤0.01%	642
2023 Q4	$33.7K	Sell	909 -360	-28%	-$12.9K	﹤0.01%	655
2023 Q3	$46K	Sell	1,269 -128	-9%	-$4.54K	﹤0.01%	592
2023 Q2	$49.8K	Sell	1,397 -640	-31%	-$23K	﹤0.01%	575
2023 Q1	$72.5K	Sell	2,037 -39	-2%	-$1.36K	﹤0.01%	519
2022 Q4	$73K	Sell	2,076 -693	-25%	-$23.1K	﹤0.01%	509
2022 Q3	$81K	Sell	2,769 -524	-16%	-$19.9K	﹤0.01%	499
2022 Q2	$179K	Buy	3,293 +239	+8%	+$13.2K	﹤0.01%	392
2022 Q1	$166K	Hold	3,054	–	–	﹤0.01%	421
2021 Q4	$168K	Hold	3,054	–	–	﹤0.01%	425
2021 Q3	$146K	Sell	3,054 -568	-16%	-$28.5K	﹤0.01%	433
2021 Q2	$180K	Sell	3,622 -40	-1%	-$1.92K	﹤0.01%	402
2021 Q1	$163K	Sell	3,662 -240	-6%	-$10.9K	﹤0.01%	421
2020 Q4	$179K	Sell	3,902 -208	-5%	-$9.55K	﹤0.01%	398
2020 Q3	$193K	Buy	4,110 +488	+13%	+$24.4K	0.01%	362
2020 Q2	$185K	Sell	3,622 -969	-21%	-$49.7K	0.01%	351
2020 Q1	$217K	Buy	4,591 +1,349	+42%	+$72K	0.01%	309
2019 Q4	$190K	Buy	3,242 +80	+3%	+$4.45K	0.01%	394
2019 Q3	$169K	Buy	3,162 +428	+16%	+$22K	0.01%	410
2019 Q2	$137K	Buy	+2,734	New	+$137K	﹤0.01%	453
2018 Q4	–	Sell	-4,712	Closed	-$237K	–	224
2018 Q3	$237K	Hold	4,712	–	–	0.01%	301
2018 Q2	$237K	Hold	4,712	–	–	0.01%	311
2018 Q1	$230K	Sell	4,712 -35	-0.7%	-$1.63K	0.01%	301
2017 Q4	$210K	Buy	4,747 +35	+0.7%	+$1.62K	0.01%	334
2017 Q3	$239K	Sell	4,712 -402	-8%	-$20.4K	0.01%	292
2017 Q2	$276K	Sell	5,114 -160	-3%	-$8.53K	0.01%	283
2017 Q1	$278K	Buy	5,274 +402	+8%	+$20.4K	0.01%	281
2016 Q4	$235K	Hold	4,872	–	–	0.01%	300
2016 Q3	$263K	Sell	4,872 -1,344	-22%	-$73.7K	0.01%	274
2016 Q2	$337K	Sell	6,216 -874	-12%	-$46K	0.02%	247
2016 Q1	$360K	Sell	7,090 -2,135	-23%	-$106K	0.02%	235
2015 Q4	$465K	Buy	9,225 +196	+2%	+$9.99K	0.02%	220
2015 Q3	$434K	Sell	9,029 -185	-2%	-$9.63K	0.02%	216
2015 Q2	$480K	Hold	9,214	–	–	0.02%	218
2015 Q1	$532K	Sell	9,214 -188	-2%	-$10.8K	0.03%	215
2014 Q4	$502K	Buy	9,402 +575	+7%	+$32.2K	0.02%	224
2014 Q3	$507K	Sell	8,827 -810	-8%	-$49.7K	0.03%	217
2014 Q2	$644K	Sell	9,637 -252	-3%	-$17.1K	0.03%	201
2014 Q1	$660K	Buy	9,889 +1,148	+13%	+$77.6K	0.03%	191
2013 Q4	$583K	Sell	8,741 -160	-2%	-$10.4K	0.03%	199
2013 Q3	$558K	Hold	8,901	–	–	0.03%	206
2013 Q2	$556K	Buy	+8,901	New	+$565K	0.03%	196

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

HM Payson & Co's GSK Position: Q2 2026 in Review

HM Payson & Co reduced its GSK (GSK) stake by 9.9% in Q2 2026, selling an estimated $25.4K and leaving 4,374 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #427.

HM Payson & Co first reported a position in GSK in Q2 2013 and has held it in 51 quarters since. The position peaked at $660K in Q1 2014. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

HM Payson & Co held 4,374 shares of GSK worth $229K as of Q2 2026.
HM Payson & Co sold 480 GSK shares in Q2 2026, an estimated $25.4K.
GSK made up ﹤0.01% of HM Payson & Co's portfolio in Q2 2026, its #427 holding.
HM Payson & Co first reported a position in GSK in Q2 2013 and has held it in 51 quarters since.
HM Payson & Co's GSK position peaked at $660K in Q1 2014.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.